Finnish healthtech Treat raised a €3M pre-seed led by byFounders and Illusian to cut repeat visits in private healthcare with AI-assisted patient intake.
Key Takeaways
- Helsinki-based Treat raised a €3M pre-seed round announced on November 17, 2026.
- byFounders and Illusian, Supercell founder Ilkka Paananen's investment company, led. Wave Ventures also took part.
- Valuation is undisclosed. Treat says 83% of cases are resolved in one visit.
Lead
Treat, a Helsinki healthtech company founded in 2026, has raised €3M in a pre-seed round led by byFounders and Illusian, the company announced on November 17, 2026. Wave Ventures also participated. The startup is building an AI-native platform that briefs a licensed doctor on a patient's case before the consultation starts, aiming to remove the repeat appointments that private care generates when a first visit is spent collecting basic information. Treat did not disclose a valuation.
What Does Treat Do?
Treat sells AI-assisted patient intake combined with remote consultations with licensed physicians. Patients describe symptoms in their own words, and an adaptive intake tool asks follow-up questions and compiles the answers into a structured brief. The platform also checks employer and insurance coverage.
According to the company, only licensed doctors can access medical records, and identifiable patient data is not shared with public large language models. Cases that cannot be settled in a single digital consultation are routed to the appropriate specialist. Treat is sold to employers as a workplace health benefit that sits alongside existing occupational healthcare and private insurance rather than replacing them.
Who Is Behind It?
The founding team is led by Sami Marttinen, the former CEO of Finnish recommerce company Swappie, who stepped down from advisory and board roles at that company last year. He is joined by medical doctor Antti Mauno and Onni Wahlberg, a fintech engineering lead.
Marttinen has described the origin of the idea as a failure of basic coordination: a family member's records went unread because nobody had time to go through them. He has also said the company's "only incentive is solving the patient's issue," a pointed contrast with clinics that earn more when patients return.
Why Did Investors Back a Pre-Seed This Fast?
The round came together quickly, closing within one week of the first investor conversations, a pace that points to the weight of the founder's track record more than a mature product. Marttinen scaled Swappie through one of the more visible Nordic consumer-tech runs of recent years, and Paananen's Illusian is a repeat backer of Finnish founders. For a company founded this year, a €3M first cheque from two lead investors is large by pre-seed standards in the Nordics, though not unusual for a team with an operating history.
Skepticism is warranted on the numbers. Treat says 83% of cases are resolved on the first visit, but that figure is the company's own and no independent benchmark has been published. The startup reports more than 20 pilot employers, mostly global businesses, including one with 1,300 employees, and thousands of active users. Pilots are not contracted revenue, and the conversion from pilot to paid deployment is the metric this round does not yet answer.
How Does the Business Model Differ From Typical Private Care?
Treat's pitch is that fragmented incentives drive inefficiency. A clinic paid per appointment gains little from resolving an issue in one visit, while an employer paying for a benefit gains from fewer absences and fewer follow-ups. By selling to employers, Treat aligns its revenue with resolution rather than volume.
That structure carries its own risk. Employer benefit budgets are contested, and occupational healthcare providers and insurers already hold those relationships. Treat is positioning itself as a complement, which lowers the barrier to adoption but also limits how much spend it can displace.
What Comes Next for Treat?
The company plans to spend the capital mainly on product development and geographic expansion. It has said it aims to be active in more than five countries by the end of the year and to reach tens of millions of people in the coming years. Both targets are ambitious for a company that is months old, and regulatory differences in telemedicine, medical record handling and insurance across European markets will shape how fast it can move.
The likely path is a Finnish and Nordic base built on employer contracts, with expansion following multinational customers into their other markets. A seed round would probably hinge on paid contracts and retention data from the current pilots.
Outlook
Treat enters a crowded field of digital health providers with a clear thesis, an experienced founder and €3M from investors with a record of backing Finnish teams. What remains unproven is whether the claimed 83% first-visit resolution rate holds at scale and whether employers will pay for it. The next funding round, not this one, will be the real test.



